{"id":7814,"date":"2026-04-09T06:30:00","date_gmt":"2026-04-09T06:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-tah-and-key-collaborators-featured-in-new-svt-documentary-series\/"},"modified":"2026-04-09T06:30:00","modified_gmt":"2026-04-09T06:30:00","slug":"realheart-tah-and-key-collaborators-featured-in-new-svt-documentary-series","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-tah-and-key-collaborators-featured-in-new-svt-documentary-series\/","title":{"rendered":"Realheart\u00ae TAH and Key Collaborators Featured in New SVT Documentary Series"},"content":{"rendered":"
\n

V\u00e4ster\u00e5s, Sweden, April 9, 2026 \u2013 Scandinavian Real Heart AB (publ) announces today that the company\u2019s artificial heart technology, its founder and inventor Dr. Azad Najar, and long-standing clinical research collaborator Professor G\u00f6ran Dellgren are featured in the new SVT documentary series Victorias Hj\u00e4rta, premiering on April 9, 2026.<\/strong><\/p>\n<\/div>\n

\n

Cardiovascular disease remains the leading cause of death in Sweden, and tens of millions of people globally suffer from heart failure. In the three-part documentary series, SVT science journalist and presenter Victoria Dyring shares her personal story of living with a congenital heart valve defect and the life-changing open-heart surgery that ultimately becomes unavoidable. The series provides a rare behind-the-scenes look at Swedish cardiac care, the existential realities of heart disease, and the medical advances that save lives every day.<\/p>\n

The documentary features an interview with Dr. Azad Najar, founder and inventor of Realheart\u00ae TAH, who shares his personal journey and the motivation that drove him to dedicate over two decades to developing a better treatment for heart failure patients. Additionally, a prototype of Realheart\u00ae TAH is showcased in the documentary, illustrating the innovative four-chamber design that mimics the structure and function of the natural human heart.<\/p>\n

Further, the series features Professor G\u00f6ran Dellgren, Chief Physician at the Transplantation Center and Thorax Clinic at Sahlgrenska University Hospital in Gothenburg, and Realheart\u2019s clinical research collaborator, as he is followed in his daily work behind the scenes. Viewers gain insight into the challenges he faces as a heart surgeon \u2013 including heart transplantation procedures \u2013 and hear him describe the role of mechanical heart pump therapy for patients with severe heart failure.<\/p>\n

\u201cRealheart\u00ae TAH is the only total artificial heart device in the world that mimics the structure and physiology of the natural human heart. We are very proud that our long-standing clinical collaborator Professor Dellgren\u2019s vital work in cardiac care and our founder Azad Najar\u2019s inspiring innovation journey are part of this important documentary. The series provides a powerful platform to raise awareness about the challenges facing heart failure patients and the urgent need for new treatment options,\u201d says Ina Laura Perkins, CEO, Realheart.<\/p>\n

The documentary is available for public viewing* on SVT Play from April 9, 2026.<\/p>\n

* The documentary can only be viewed in Sweden.<\/em><\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart\u00ae TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se<\/a><\/p>\n<\/div>\n

\n

Attachments<\/strong>
Realheart\u00ae TAH and Key Collaborators Featured in New SVT Documentary Series<\/a><\/p>\n<\/div>\n